Study #2017-0350
Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Viral Specific T Cells for Therapy of Adenovirus Related Disease in Immunocompromised Patients
MD Anderson Study Status
Enrolling
Treatment Agent
Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Description
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Study phase:
Phase I
Physician name:
David Marin
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.